Homeobox genes encode transcription factors that are essential for normal development and are often dysregulated in cancers. The molecular mechanisms that cause their misregulation in cancers are largely unknown. In this study, we investigate the mechanism by which the Six1 homeobox protein, which has a crucial role during development, is frequently deregulated in several poor outcome, aggressive, metastatic adult human cancers, including breast cancer, ovarian cancer, hepatocellular carcinoma and pediatric malignancies such as rhabdomyosarcoma and Wilms' tumor. Our results reveal that miRNA-185 translationally represses Six1 by binding to its 3 0 -untranslated region. Analyses of ovarian cancers, pediatric renal tumors and multiple breast cancer cell lines showed decreased miR-185 expression, paralleling an increase in Six1 levels. Further investigation revealed that miR-185 impedes anchorage-independent growth and cell migration, in addition to suppressing tumor growth in vivo, implicating it to be a potent tumor suppressor. Our results indicate that miR-185 mediates its tumor suppressor function by regulating cell-cycle proteins and Six1 transcriptional targets c-myc and cyclin A1. Furthermore, we show that miR-185 sensitizes Six1-overexpressing resistant cancer cells to apoptosis in general and tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-mediated apoptosis in particular. Together, our findings suggest that the altered expression of the novel tumor suppressor miR-185 may be one of the central events that leads to dysregulation of oncogenic protein Six1 in human cancers.
Introduction
Tumor growth and metastasis is partly derived from deregulation of genes that are critical regulators of normal developmental and differentiation. One group of genes that has a crucial role in both development and tumorigenesis is the homeobox gene family. Although much is known about the function of homeobox genes, relatively little is known about their regulation, particularly in cancers. One homeobox gene of interest is the Six1 homeoprotein, which has an important role in the expansion of progenitor cell populations during early embryogenesis (Grifone et al., 2005) and is known to be essential for the development of numerous organs (Li et al., 2003; Zheng et al., 2003; Ozaki et al., 2004) . In addition, Six1 is reported to be overexpressed in multiple pediatric and adult human cancers, including breast (Ford et al., 1998) , ovarian (Behbakht et al., 2007) , cervical (Wan et al., 2008) and hepatocellular carcinomas (Ng et al., 2006) , as well as rhabdomyosarcomas and Wilms' tumors (Li et al., 2002; Yu et al., 2004) . It is important to note that Six1 overexpression has been strongly associated with aggressive, metastatic cancers and poor prognosis (Coletta et al., 2004; Yu et al., 2004; Behbakht et al., 2007) . Recently, Six1 overexpression in immortalized mammary epithelial cells has been shown to induce transformation, leading to highly aggressive and invasive tumors in nude mice (Coletta et al., 2008) . Despite Six1's important role during development and frequent deregulation in a large number of neoplasms, surprisingly little is known about its regulation. As microRNAs (miRNAs) have recently attracted significant attention as master regulators of gene expression and increasing evidence suggests that they can function as tumor suppressors or oncogenes (Vasilatou et al., 2009) , we proposed that miRNAs may have a role in controlling Six1 expression. In this study, we identify miR-185 to be responsible for regulating Six1 expression in cancers. We show that miR-185, which is located at 22q11.21, directly targets the 3 0 -untranslated region (UTR) of Six1 transcripts and elicits a specific and robust downregulation of Six1 protein. Our results reveal a reciprocal relationship between Six1 and miR-185 in pediatric renal and adult ovarian tumors and breast cancer cell lines, in which Six1 overexpression parallels miR-185 underexpression. Further investigation reveals that miR-185 is a potent tumor suppressor, as it inhibits cell proliferation, anchorage-independent growth and cell invasion, as well as tumor growth in immunocompromised mice. In addition, we show that miR-185 mediates its antiproliferative and tumor suppressor functions in part by suppressing the expression of Six1 transcriptional targets c-myc and Cyclin A1 and by sensitizing cancer cells to programmed cell death in general and to TRAIL-mediated apoptosis in particular. Our findings further support the notion that miRNAs are critical regulators of tumorigenesis.
Results and Discussion
miR-185 expression correlates reciprocally with Six1 gene expression in cancer Although the Six1 homeobox gene is known to have a central role in the development of multiple aggressive solid tumors and is associated with poor patient survival, the mechanism by which Six1 is dysregulated in cancers is not known. As miRNAs have recently been shown to regulate the expression of several genes involved in tumorigenesis, we predicted that they may also have an important role in modulating Six1 expression in cancers. Target prediction algorithm TargetScan (http://www.targetscan.org/) predicted 16 miRNAs to target Six1. Out of these, miR-185 was predicted by six other prediction algorithms, including miRanda, mirTarget2, miTarget, PITA, RNA22 and RNA hybrid, to regulate Six1. Furthermore, miR-185 was found to be evolutionarily conserved throughout vertebrates, suggesting it to have an important function across a variety of species. Moreover, of all the predicted miRNAs, only miR-185 had perfect inverse correlation with Six1 expression in multiple human cancers, including pediatric renal tumors ( Figure 1a ) and aggressive ovarian cancers (Figure 1b) , when compared with their corresponding normal tissues. This higher expression of Six1 and significantly lower expression of miR-185 also corresponded with a similar expression pattern in multiple breast cancer cell lines, as compared with early passage human mammary epithelial cells (Figure 1c) , further suggesting misregulation of miR-185 to be a frequent event responsible for Six1 overexpression in human cancers.
miR-185 targets the 3
0 -UTR of the Six1 homeobox gene Because miRNAs generally regulate gene expression by binding to the 3 0 -UTRs of their target genes, we predicted that miR-185 represses Six1 expression levels by binding to its 3 0 -UTR. Bioinformatics analyses revealed that Six1 3 0 -UTR contained one putative miR-185 binding site for miR-185 (Figure 1d ). To examine whether miR-185 indeed binds to the Six1 3 0 -UTR at its putative binding site, human embryonic kidney (HEK)-293 cells were transfected with pMIRReport vector construct containing the Six1 3 0 -UTR (Figure 1d ), and luciferase activity was measured. As shown in Figure 1e , luciferase activity was significantly repressed in pMIR-Six1 3 0 -UTR-transfected cells when compared with the null construct, suggesting that Six1 expression levels may be regulated by miRNA/s binding to sequences within its 3 0 -UTR. To further substantiate this finding, we determined the activity of a construct containing only the miR-185 binding sequence in triplicate (Figure 1d ). Our results show that miR-185 triplicated binding sequence elicited a more robust translational repression of luciferase activity when compared with the full 3 0 -UTR of Six1, which contains a single miR-185 binding site, suggesting that this sequence is a bona fide miR-185 binding site (Figure 1e ). Supporting these findings, we found that luciferase activities of both the Six1 3 0 -UTR-and triplicate miR-185 binding sequence-containing constructs were further repressed in cells overexpressing the miR-185 mimic (Figure 1e ). In contrast, mutation of the seed sequence binding site in the Six1 3 0 -UTRcontaining construct (Figure 1d ) not only restored luciferase activity to near that of the wild-type construct but also rendered transcripts from this construct insensitive to miR-185 overexpression (Figure 1e ), confirming a specific interaction between miR-185 and the predicted binding site in Six1's 3 0 -UTR. Finally, we assessed the effect of miR-185 on Six1 protein levels by performing western blot analysis in the ovarian cancer cell line SKOV3, which is known to highly express Six1 (Behbakht et al., 2007) and HEK-293 cells that show comparatively lower Six1 expression. Overexpression of miR-185 mimic in SKOV3 resulted in significantly reduced (70-80%) Six1 protein expression levels ( Figure 1f , left panel, and Supplementary Figure S1 ). In contrast, silencing of miR-185 using a specific miR-185 inhibitor in HEK-293 (Figure 1f , right panel) and SKOV3 cells (Supplementary Figure S1 ) resulted in marked induction (Bthree-to fivefold) of Six1 protein levels. Real-time PCR analysis showed that Six1 mRNA levels were also reduced (although less drastic than protein levels) (Supplementary Figure S2c) in miR-185-overexpressing cells, indicating that miR-185 regulates Six1 expression in human cancers both at the RNA and protein levels. miR-185 inhibits colony formation in vitro and tumor growth in vivo by suppressing Six1
The significantly decreased expression of miR-185 in tumor tissues and multiple cancer cell lines prompted us to examine the contribution of miR-185 in tumorigenesis. To determine this, we first examined the effect of miR-185 on cell proliferation, a property known to be promoted by Six1. miR-185 overexpression in HEK-293 cells resulted in significantly reduced cellular proliferation ( Figure 2a , left panel), whereas inhibition of miR-185 led to increased cellular viability (Figure 2a , right panel). More important, overexpression of Six1 cDNA partially restored cell growth, suggesting that miR-185 inhibits cell growth and viability through its repression of Six1 (Figure 2b ). In addition, we ruled out ) and a normal human mammary epithelial cell line (specimen 184, Lawrence Berkeley National Laboratory, Berkeley, CA, USA) (c). Total RNA was extracted using the miRNEasy Mini kit (Qiagen, Germantown, MD, USA). A volume of 2 mg of total RNA was reverse transcribed using the miScript RT kit (Qiagen) and real-time PCR was performed with a forward primer specific to miR-185 or a primer set specific to Six1 using the miScript SYBR Green PCR kit (Qiagen). Replicate reactions were run for each cDNA sample. The relative expression of each gene was quantified by measuring Ct values and normalizing against RNU19 or 18S for miRNA or gene expression, respectively. (d) Schematic of the putative miR-185 binding sequence in the Six1 3 0 -UTR, and diagrams of the luciferase reporter constructs (pMIR-Report) containing either the Six1 3 0 -UTR, Six1 3 0 -UTR with mutated seed sequence of miR-185 binding site (3 0 -UTR-mut) or triplicated miRNA binding sequences (3X-miR-185). For the pMIR-Six1 3 0 -UTR construct, the wild-type 3 0 -UTR segment of the Six1 gene was amplified using genomic DNA and subcloned downstream of the luciferase gene in the pMIR-Report vector (Ambion, Austin, TX, USA) at SacI and SpeI sites. The pMIR-Six1 3 0 UTR-mut construct was generated by performing site-directed mutagenesis with primers spanning the miRNA binding site with indicated mutations. To generate the miR-185 triplicate construct (3X-miR-185), an oligonucleotide containing the triplicated miR-185 binding sequence in the Six1 3 0 -UTR (B80 nt) was annealed with its complementary sequence and cloned in pMIR-Report vector at SacI and SpeI sites. (e) Validation of the Six1 3 0 -UTR as a miR-185 target. HEK-293 cells were plated at 55% confluency in six-well plates. pMIR-Report constructs were co-transfected with control PRL-CMV using Lipofectamine 2000 as per the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Luciferase activity was measured 48 h after transfection using the Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA) on a Glomax 20/20 Luminometer (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity for each transfected well. For overexpression studies, 10 nM negative control miRNA or miR-185 mimic (Applied Biosystems, Foster City, CA, USA) was transfected 24 h after transfection of either pMIR-Six1 3 0 UTR, pMIR-3X-miR-185 or pMIR-Six1 3 0 UTR-mut luciferase constructs. The mean of four independent experiments (performed in duplicate for each experiment); bars, s.e.m. *Po0.05; **Po0.01; ***Po0.001, comparison between two groups as indicated. (f) miR-185 regulates Six1 protein expression. Western blot analyses of SKOV3 (left panel) and HEK-293 (right panel) cells transfected with 10 nM negative control miRNA, miR-185 mimic (for 3 days) or miR-185 inhibitor (for 5 days, Applied Biosystems) using anti-Six1 antibody (1:500; rabbit polyclonal, M120, Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by HRP-conjugated goat antirabbit secondary antibody (SC-2004, Santa Cruz Biotechnology) and detected with Amersham ECL plus detection kit (GE Healthcare Life Sciences, Piscataway, NJ, USA). Protein loading was estimated with mouse anti-b-actin monoclonal antibody (AC-74, Sigma, St Louis, MO, USA). A volume of 10, 20 or 40 mg of indicated samples was resolved on 12% (w/v) SDS-polyacrylamide gel electrophoresis and transferred to a Millipore nylon membrane. Gel photograph is representative of four independent experiments. Band intensities were quantified with the Total Labs TL100 1D gel analysis software (nonlinear, bottom panels); s.e.m. ***Po0.001.
any nonspecific effects of miR-185 overexpression by rescuing the miR-185 phenotype with comparable levels of miR-185 inhibitor (Figure 2b ) and by observing a comparatively similar phenotypic effect of miR-185 at varying concentrations ranging from 2.5 to 50 nM (Supplementary Figure S2) . Next, we performed softagar colony formation assays to assess whether miR-185 inhibits anchorage-independent growth. For our in vitro and in vivo tumorigenicity assays, we used miR-185 stably expressing HEK-293 cells passaged over 52 times, which are reported to be highly tumorigenic and cause tumor growth in immunocompromised mice (Shen et al., 2008) . miR-185 stably overexpressing cells expectedly showed significantly lower Six1 levels (Supplementary Figure S3 ) and exhibited drastically reduced colony-forming capacity (colony number, size and nutrient consumption) when compared with vector control, suggesting a potential tumor suppressor-like activity (Figure 3a and Supplementary Figure S4 ). More important, this effect could be largely reversed by the addition of either Six1 cDNA or miR-185 inhibitor (Figure 3a) . To confirm these findings in vivo, vector control HEK-293 cells and miR-185 stable HEK-293 cells overexpressing control, Six1 cDNA or miR-185 inhibitor were injected subcutaneously into the flanks of SCID mice, and tumor growth was evaluated for 30 days starting from day 10 after injection. In contrast to the vector control xenografts, miR-185-overexpressing tumors grew significantly slower (Figures 3b and c) , and were partially rescued either by Six1 or miR-185 inhibitor overexpression, indicating a Cell growth relative to miRNA control was measured by neutral red assay as described previously (Repetto et al., 2008) . Mean of at least three independent experiments (performed in triplicate for each experiment). Figure 3 miR-185 inhibits anchorage-independent growth in vitro and tumor growth in vivo. For the generation of pSilencer miR-185 construct, B450 bp pri-miR-185 genomic sequence was amplified using normal kidney genomic DNA as a template (extracted with the Red Ex-N-Amp kit (Sigma)) and cloned in BamHI and HindIII sites of the pSilencer 4.1 puro vector (Ambion). HEK293 cells were then transfected with either pSilencer scramble or pSilencer miR-185 and selected with puromycin for 14 days. (a) PSilencer scramble (control) and pSilencer miR-185 stable lines further transfected with 25 ng of either KS þ control (labeled as miR-185), Six1 cDNA expression plasmid (miR-185 þ Six1) or 10 nM miR-185-specific inhibitor (miR-185 þ inhibitor) were subjected to soft-agar colonyformation assays. Briefly, 1 ml of 0.5% agarose in Dulbecco's Modified Eagle's Medium with 20% FBS was plated in each well of a 12-well plate and left to set for 20 min. This layer was overlaid with 5000 stably transfected HEK-293 cells in 2.5 ml of 0.34% agarose diluted in Dulbecco's Modified Eagle's Medium with 20% FBS. Cells were incubated as normal for 10 days, after which wells were photographed to show nutrient consumption (Supplementary Figure S4 ) and colonies were counted (right panel) using the Total Labs TL100 colony counting software (Nonlinear). Results are the average of three independent experiments; bars, s.e.m. *** a (control vs miR-185), Po0.001; *** b (miR-185 vs miR-185 þ Six1), Po0.001; *** c (miR-185 vs miR-185 þ inhibitor), Po0.001. (b) Overexpression of miR-185 inhibits tumor formation in SCID mice. HEK-293 (2 Â 10 6 ) cells stably overexpressing either pSilencer scramble (control) or pSilencer miR-185, which were further transfected with 25 ng of either KS þ control (labeled as miR-185), Six1 cDNA expression plasmid (miR-185 þ Six1) or 10 nM miR-185-specific inhibitor (miR-185 þ inhibitor), were injected subcutaneously into the flanks of RAG2 À/À , gc À/À (purchased from Taconic, Germantown, NY, USA) SCID male mice (control, n ¼ 9; miR-185, n ¼ 9; miR-185 þ Six1, n ¼ 6; mir-185 þ inhibitor, n ¼ 6), using a 50 ml glass syringe with a 22-gauge blunt needle (Hamilton, Reno, NV, USA). Tumor volume was assessed every five days starting from day 10 until the animals were killed 30 days after transplantation. the migration capability of SKOV3 cells in a Transwell chemotaxis assay, whereas the overexpression of either Six1 or miR-185 inhibitor was able to significantly rescue cell migration (Figure 3d) . Collectively, these results clearly show that miR-185 has properties consistent with that of a potent tumor suppressor.
miR-185 alters cell-cycle progression and sensitizes cells to apoptosis through Six1
To directly address miR-185 specificity and Six1's involvement in miR-185-regulated antiproliferative and tumor suppressor activity, we determined the levels of the Six1 transcriptional targets and cell-cycle regulators cyclin A1 and c-myc (Coletta et al., 2004; Yu et al., 2006) . We found that miR-185 overexpression resulted in significantly decreased levels of cyclin A1 and c-myc, which were rescued with overexpression of either Six1 cDNA or miR-185 inhibitor, in all cell lines tested (Figure 4a , data not shown). As Six1 overexpression has been shown to attenuate the DNA damage-induced G2 checkpoint (Ford et al., 1998) , we next investigated whether mir-185 affects cell-cycle progression. Propidium iodide (PI) staining of miR-185-overexpressing HEK-293 cells revealed an increase in G1 and G2 cell populations and a decrease in cells in S phase (Figure 4b) , suggesting a block in the G1/S phase transition of the cell cycle. More important, this effect Graph representing quantitative real-time PCR analysis on total RNA isolated from SKOV3 cells transfected first with 10 nM negative control miRNA or miR-185 mimic for 12 h, after which the miR-185 mimic-transfected cells were further transfected with 25 ng KS þ control ( þ miR-185, -Six1), Six1 cDNA expression plasmid ( þ Six1) or 10 nM miR-185-specific inhibitor ( þ inhibitor) for an additional 60 h, using primers specific for cyclin A1 and c-myc; bars, s.e.m. **Po0.01, comparison between two groups as indicated. (b) Histograms of PI staining of HEK-293 cells transiently transfected with 10 nM negative control miRNA (control) or miR-185 mimic, after which miR-185 mimic-transfected cells were further transfected with 25 ng of either KS þ control (labeled as miR-185), Six1 cDNA expression plasmid (miR-185 þ Six1) or 10 nM miR-185-specific inhibitor (miR-185 þ inhibitor). Briefly, 20 000 transfected HEK-293 cells were fixed in 100% methanol, resuspended in 250 ml PI staining solution (0.01% Tween/phosphate-buffered saline, 5 mg/ml DNAse-free RNAse A, 0.5 mg/ml PI) and analyzed for cell-cycle progression with a FACSCanto flow cytometer (BD Biosciences, San Jose, CA, USA) and FlowJo flow cytometry analysis software. The miR-185 histogram shows an increase in the percentage of cells in G0/G1 and a decrease in S phase as compared with control, which is reversed on overexpression of either Six1 or miR-185 inhibitor. G1, S and G2 percentages for each histogram are the average of triplicate experiments. (c-e) miR-185 overexpression increases cellular sensitivity to apoptosis. (c, d) miR-185 increases the sensitivity of serum-starved cells to apoptosis as determined by Annexin V/PI staining using the FITC Annexin V Apoptosis Detection Kit (BD Pharmingen, San Diego, CA, USA) (c), and by activation of caspase-3 and -7, which was determined using the caspase-Glo 3/7 assay kit (Promega), according to the manufacturer's instructions. HEK-293 cells were transfected with 10 nM negative control miRNA (control) or miR-185 mimic, after which miR-185 mimic-transfected cells were further transfected with 10 nM negative control miRNA (labeled as miR-185) or 10 nM miR-185-specific inhibitor (miR-185 þ inhibitor) in triplicate wells and starved for 48 h before harvesting. Cells were trypsinized and resuspended in 250 ml Annexin V binding buffer and incubated with 5ul Annexin and 5 ml PI (50 mg/ml) for 15 min, after which the cells were washed and resuspended in 1X phosphate-buffered saline and analyzed with a FACS Canto flow cytometer (BD Biosciences) and FlowJo flow cytometry analysis software. The percentage cell population shown in Quarters 1, 2 and 4 (Q1, Q2 and Q4) represents the average of multiple experiments. For caspase-3 and -7 activation (d), HEK-293 cells were transfected with 10 nM negative control miRNA (control) or miR-185 mimic, after which miR-185 mimic-transfected cells were further transfected with 25 ng of either KS þ control (labeled as miR-185), Six1 cDNA expression plasmid (miR-185 þ Six1) or 10 nM miR-185-specific inhibitor (miR-185 þ inhibitor) and starved for 48 h. These cells were treated with Caspase-Glo buffer (equivalent to the volume of media) for 30 min, after which samples were analyzed on a Glomax 20/20 Luminometer (Promega). Shown is the mean of at least three independent experiments; bars, s.e.m. *** a (control vs miR-185), Po0.001; *** b (miR-185 vs miR-185 þ Six1), Po0.001; *** c (miR-185 vs miR-185 þ inhibitor), Po0.001. (e) miR-185-mediated sensitization of resistant SKOV3 cells to TRAIL-induced cell death. A total of 3000 SKOV3 cells per well (in triplicate) were transfected with either control, miR-185, Six1 or inhibitor as described in (d) for 48 h, followed by treatment with varying concentrations of full-length recombinant human TRAIL for 24 h. Cell viability was assessed by neutral red assay. Shown is the mean of triplicate experiments. could be partially rescued by the overexpression of Six1 or miR-185 inhibitor (Figure 4b ). These findings indicate that miR-185 may mediate its antiproliferative and tumor suppressor-like activity in part by altering cell-cycle progression and inhibiting expression of cellcycle regulators and Six1 transcriptional targets cyclin A1 and c-myc, inappropriate activation of which are known to promote cell proliferation and tumor growth (Li et al., 2003; Coletta et al., 2004; Yu et al., 2006) .
To further understand the mechanism of miR-185 tumor suppressor activity, we investigated the effect of miR-185 on apoptosis, as evasion of apoptosis is a crucial event during malignant transformation. Interestingly, we found that, compared with negative control miRNAtransfected cells, miR-185 overexpression resulted in a significant increase (approximately two-fold; compare Q2 þ Q4 in control with miR-185, Figure 4c ) in early apoptotic and late apoptotic/necrotic activity of cells after serum starvation, as determined by Annexin V staining. Furthermore, PI staining showed a 39% increase in total cell death in miR-185-overexpressing cells when compared with control (compare Q1 in control with miR-185, Figure 4c ). Addition of a specific inhibitor to miR-185-treated cells partially rescued the cells from loss of membrane integrity and cell death. Consistent with our previous result, compared with control, miR-185-overexpressing serum-starved cancer cells showed a significant (greater than three-fold) increase in caspase-3/7 activity, which was restored with ectopic expression of either Six1 or miR-185 inhibitor ( Figure 4d ). As adaptation to low nutrition is presumed to be one of the prerequisites for cancers cells to survive in their tumor microenvironment, our results showing that miR-185 sensitizes cancer cells to serum starvation-induced apoptosis suggest a critical role for miR-185 in this process. Furthermore, to specifically address the role of Six1 in miR-185-mediated apoptosis, we determined the effect of miR-185 on the TRAIL apoptotic pathway, as constitutively higher Six1 expression is known to confer resistance to TRAIL-mediated apoptosis (Behbakht et al., 2007) . Cell survival studies revealed that SKOV3 cells transfected with miR-185 became more sensitive to TRAIL compared with SKOV3 cells transfected with miRNA control (Figure 4e ). More important, either Six1 or miR-185 inhibitor overexpression was able to restore resistance to TRAIL-mediated apoptosis, suggesting a direct involvement of Six1 in this process. Although interesting, our observation that cell lines such as MDA-MB-231, previously reported to be TRAIL sensitive, can also have lower miR-185 levels and higher Six1 expression levels (Figure 1c) suggests that the miR-185-Six1 signaling pathway may not be the only pathway that regulates TRAIL resistance, and that some Six1-overexpressing tumors and cancer cell lines may exhibit TRAIL resistance in a Six1-independent manner.
Conclusions
Aberrant Six1 overexpression in numerous human cancers has been shown to result in increased proliferation, tumor cell survival, drug resistance and metastasis (Coletta et al., 2004; Yu et al., 2004; Reichenberger et al., 2005; Behbakht et al., 2007) . Our results showing lower levels of miR-185 and increased levels of Six1 expression in multiple human cancers indicate that miR-185 may be a critical regulator of Six1 pro-proliferative role and that loss of miR-185 expression may be one of the important events in Six1-mediated tumorigenesis. As Six1 is known to induce normal cell proliferation during development, it is likely that uncontrolled Six1 expression because of significantly lower levels of its regulator miRNA/s, such as miR-185, during early development may lead to persistent proliferation and neoplastic transformation of precursor cells, resulting in pediatric tumor growth. Similarly, reduced levels of miR-185 resulting in altered expression of Six1 in differentiated tissues may in part lead to the reinitiation of developmental cell proliferative pathways in Six1-overexpressing adult tumors. In agreement with this, Six1-induced mammary epithelial to mesenchymal transition has been associated with increased mammary stem/progenitor cell self-renewal and tumorigenesis (McCoy et al., 2009; Radisky, 2009) . Furthermore, Six1 transcriptional target cyclin A1, which is normally expressed in embryonic but not in differentiated mammary gland, when reactivated because of uncontrolled Six1 expression, results in increased proliferation of breast cancer cells (Coletta et al., 2004) .
Adding to the increasing role of miRNAs in cancer, our findings of a novel tumor suppressor miRNA, miR-185, targeting Six1 oncogene is highly significant, as Six1 is reported to be involved in tumorigenesis of several pediatric and adult cancers. Furthermore, our finding of miR-185-mediated sensitization of resistant cells to TRAIL-mediated apoptosis is significant, as TRAIL has been proposed to affect several aspects of tumorigenesis, including inhibition of tumor growth and metastasis, surveillance against tumor growth and response to chemotherapy (Shin et al., 2001; Cretney et al., 2002; El-Deiry, 2003a, b, 2004) . Therefore, future studies aimed at developing strategies to use miR-185 as a therapeutic regimen will not only result in slower tumor growth and decreased tumor invasiveness but will also lead to increased sensitivity of cancer cells to TRAIL-induced apoptosis. In addition, as Six1 is crucial for normal development, a complete understanding of the mechanism of miR-185 regulation in normal developmental and differentiation events will provide valuable insights into the complex pathways that are inappropriately activated in cancers.
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